Differential effects of enzymatic treatments on the storage and secretion of von Willebrand factor by human endothelial cells

被引:26
作者
Lopes, AAB
Peranovich, TMS
Maeda, NY
Bydlowski, SP
机构
[1] Pro Sangue Fdn, Hemoctr Sao Paulo, Lab Pesquisa Biotecnol, BR-05403000 Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil
[3] Univ Sao Paulo, Dept Hematol, Sao Paulo, Brazil
关键词
endothelial cell; von Willebrand factor; cell culture; cell passaging; trypsin;
D O I
10.1016/S0049-3848(00)00401-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Enzymatic treatment used for passaging of endothelial cells may induce release of von Willebrand factor (vWF). Deceased ability to replenish intracellular stores results in decreased secretion of vWF in later passages of cells. Since both trypsin. and pancreatin complex have been used for passaging endothelial cells, we analyzed the effects of successive passaging with these two enzyme preparations on the storage and secretion of VWF by human umbilical vein endothelial cells (HUVECs). Measurements were performed after the second to fifth passages. Cytoplasmic vWF was analyzed by indirect immunofluorescence and secreted vWF was measured in the supernatant of cultured HUVECs by ELISA. In trypsin-passaged cells, secreted vWF decreased progressively from passages 2 to 5. Respective concentrations were 355.0 +/- 30.4, 201.0 +/- 84.5, 150.0 +/- 1.4 and 120.5 +/- 38.9 ng vWF/10(5) cells. Comparatively, pancreatin-passaged cells secreted even less vWF protein (P = .001) at passages 4 and 5 (108.5 +/- 12.0 and 100.0 +/- 4.2 ng/10(5) cells, respectively) and had less vWF-positive cytoplasmic granules per cell. Thus, in experiments involving measurements. of endothelial vWF, the use of low passage cells is recommendable and passaging with a pure trypsin preparation appears to be more appropriate. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 24 条
[1]   HORMONE AND NEUROTRANSMITER RECEPTORS IN AN ESTABLISHED VASCULAR ENDOTHELIAL CELL LINE [J].
BUONASSISI, V ;
VENTER, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (05) :1612-1616
[2]  
COLLINS PW, 1993, THROMB HAEMOSTASIS, V70, P346
[3]  
FURIE B, 1982, J BIOL CHEM, V257, P3875
[4]   ENHANCED RELEASE OF VONWILLEBRAND-FACTOR BY HUMAN-ENDOTHELIAL CELLS IN CULTURE IN THE PRESENCE OF PHORBOL-MYRISTATE ACETATE AND INTERLEUKIN-1 [J].
GIDDINGS, JC ;
SHALL, L .
THROMBOSIS RESEARCH, 1987, 47 (03) :259-267
[5]   CHANGES IN CYTOSOLIC CA-2+ASSOCIATED WITH VONWILLEBRAND-FACTOR RELEASE IN HUMAN-ENDOTHELIAL CELLS EXPOSED TO HISTAMINE - STUDY OF MICROCARRIER CELL MONOLAYERS USING THE FLUORESCENT-PROBE INDO-1 [J].
HAMILTON, KK ;
SIMS, PJ .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (02) :600-608
[6]  
HATTORI R, 1989, J BIOL CHEM, V264, P7768
[7]  
Hattori R, 1988, CIRCULATION, V78, pII
[8]   Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells [J].
Jahroudi, N ;
Ardekani, AM ;
Greenberger, JS .
BLOOD, 1996, 88 (10) :3801-3814
[9]  
KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647
[10]  
Langer F, 1999, BRIT J HAEMATOL, V105, P542